VaccinesNews.net

Vaccines Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

During December 14–23, 2020, after administration of 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine ( 1,177,527 doses in females, 648,327 doses in males, and 67,506 doses missing sex ), rep ...


The safety of Comirnaty was evaluated in participants 16 years of age and older in 2 clinical studies that included 21,744 participants that have received at least one dose of Comirnaty. In Study 2, ...


EMA ( European Medicines Agency ) has granted conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVID-19 ) in peopl ...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 ( COVI ...


The U.S. Food and Drug Administration ( FDA ) has issued an emergency use authorization ( EUA ) for the second vaccine for the prevention of coronavirus disease 2019 ( COVID-19 ) caused by severe acut ...


The Pfizer-BioNTech COVID-19 vaccine contains a nucleoside-modified messenger RNA ( modRNA ) encoding the viral spike glycoprotein ( S ) of SARS-CoV-2. Known risks The vaccine has been shown t ...


The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S a ...


The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARSCoV-2 S an ...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe COVID-19 are still lacking for this vulnerab ...


There is a large global effort to develop vaccines for protection against COVID-19 and at least 19 vaccine candidates have, as of 31 July 2020, entered clinical trials, including phase 2 and 3 trials. ...


Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and oropharynx. Most HPV infections are asymptomatic and clear spontaneously within ...


The FDA ( U.S. Food and Drug Administration ) has approved TPOXX ( Tecovirimat ), the first drug with an indication for treatment of smallpox. Though the World Health Organization ( WHO ) declared s ...


Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at risk of cervical cancer can also be vaccinated. Data from the inte ...


It has been assessed the risk of maternal, fetal, and neonatal outcomes associated with the administration of an MF59 adjuvanted A/H1N1 vaccine during pregnancy. The trial was conducted in singleto ...


The objective of a study was to measure the effectiveness of the quadrivalent human papillomavirus ( HPV ) vaccine against cervical abnormalities four years after implementation of a nationally funded ...